Prognostic criteria in patients with gastrointestinal stromal tumors: a single center experience retrospective analysis

被引:12
|
作者
Tanimine, Naoki [1 ]
Tanabe, Kazuaki [1 ]
Suzuki, Takahisa [1 ]
Tokumoto, Noriaki [1 ]
Ohdan, Hideki [1 ]
机构
[1] Hiroshima Univ, Dept Surg, Grad Sch Biomed Sci, Div Frontier Med Sci,Minami Ku, Hiroshima 7348551, Japan
来源
WORLD JOURNAL OF SURGICAL ONCOLOGY | 2012年 / 10卷
关键词
gastrointestinal stromal tumor (GIST); prognostic criteria; recurrence; nomogram; adjuvant therapy; C-KIT MUTATION; IMATINIB MESYLATE; TYROSINE KINASE; POOR-PROGNOSIS; DOSE IMATINIB; TRIAL; DIAGNOSIS; PATHOLOGY; RESECTION; SURVIVAL;
D O I
10.1186/1477-7819-10-43
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Gastrointestinal stromal tumors (GISTs) are morphologically and clinically heterogeneous tumors, and their biological behavior is difficult to predict, ranging from clinically benign to malignant. The aim of our study was to reanalyze the value of the commonly used prognostic criteria and recently reported nomogram in predicting disease recurrence in patients with primary resectable GISTs. Methods: The clinicopathological features of 60 patients with GISTs who underwent surgical resection between 1998 and 2010 at Hiroshima University Hospital were retrospectively reviewed. Tumors were classified according to the National Institutes of Health and Armed Forces Institute of Pathology criteria, and nomogram predictions were performed. The relationship between patient and tumor characteristics was tested by univariate analysis using the log-rank test. Furthermore, we assessed nomogram performance with the concordance index and calibration. Results: The median patient follow-up was 4.1 years, with 6 of 60 patients experiencing recurrence. Recurrence was observed only in the high-risk group. The recurrence-free survival (RFS) was 93.0 and 89.9% after 2 and 5 years, respectively. The concordance indices of the nomogram prediction were 0.96 and 0.65 for all patients and the high-risk subgroup, respectively. Calibration of the nomogram-predicted RFS tended to overestimate the recurrence risk relative to the actual RFS. Conclusions: Although the commonly used criteria provide an excellent estimation of tumor behavior, they are limited by prognostic heterogeneity. The predictive nomogram is a beneficial scoring system but not a direct RFS predictor. We need more consideration for small GISTs, particularly those less than 3 cm in diameter, and small GISTs should be analyzed as a subset with potentiality different biological behavior.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Factors Affecting Recurrence-free Survival in Gastric Gastrointestinal Stromal Tumors: A Single Center Experience
    Sakin, Aysegul
    Aldemir, Mehmet Naci
    HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI, 2020, 58 (04): : 327 - 332
  • [32] Gastrointestinal Stromal Tumors: Our Ten-Year Experience of a Single-Center Tertiary Hospital
    Tzikos, Georgios
    Menni, Alexandra-Eleftheria
    Krokou, Despoina
    Vouchara, Angeliki
    Doutsini, Soultana
    Karlafti, Eleni
    Karakatsanis, Anestis
    Ioannidis, Aristeidis
    Panidis, Stavros
    Papavramidis, Theodosios
    Michalopoulos, Antonios
    Paramythiotis, Daniel
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (08):
  • [33] Gastrointestinal stromal tumors: prognostic factors and therapeutic implications
    Rosa, Fausto
    Alfieri, Sergio
    Tortorelli, Antonio Pio
    Di Miceli, Dario
    Papa, Valerio
    Doglietto, Giovanni Battista
    TUMORI JOURNAL, 2012, 98 (03): : 351 - 356
  • [34] Surgical outcomes of gastrointestinal stromal tumors of the stomach: a single unit experience in the era of targeted drug therapy
    Huang, Hai
    Liang, Han
    Zhan, Zhong-Li
    Li, Hui
    Ren, Xiu-Bao
    Hao, Xi-Shan
    MEDICAL ONCOLOGY, 2012, 29 (02) : 941 - 947
  • [35] Gastrointestinal stromal tumors of the stomach: A 10-year experience of a single-center
    Uzunoglu, H.
    Tosun, Y.
    Akinci, O.
    Baris, B.
    NIGERIAN JOURNAL OF CLINICAL PRACTICE, 2021, 24 (12) : 1785 - 1792
  • [36] Gastrointestinal Stromal Tumors: Clinical Symptoms, Location, Metastasis Formation, and Associated Malignancies in a Single Center Retrospective Study
    Aghdassi, Ali
    Christoph, Agnes
    Dombrowski, Frank
    Doering, Paula
    Barth, Christoph
    Christoph, Jan
    Lerch, Markus M.
    Simon, Peter
    DIGESTIVE DISEASES, 2018, 36 (05) : 337 - 345
  • [37] Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors A single-center analysis
    Wang, Jian
    Yin, Yuan
    Shen, Chaoyong
    Yin, Xiaonan
    Cai, Zhaolun
    Pu, Lin
    Fu, Wei
    Wang, Yaxuan
    Zhang, Bo
    MEDICINE, 2020, 99 (09)
  • [38] Results on prognostic value of mutations in localized gastrointestinal stromal tumors (GIST) in one single center
    Garces-Albir, Marina
    Marti-Obiol, Roberto
    Lopez-Mozos, Fernando
    Calabuig-Farinas, Silvia
    Navarro-Ros, Samuel
    Ortega-Serrano, Joaquin
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2012, 104 (08) : 405 - 410
  • [39] Retrospective analysis of prognostic factors affecting the recurrence and disease-free survival following surgical management of gastrointestinal stromal tumors
    Senol, Kazim
    Ozdemir, Gul Daglar
    Akat, Arif Zeki
    Kama, Nuri Aydin
    TURKISH JOURNAL OF SURGERY, 2020, 36 (02) : 209 - 217
  • [40] Gastrointestinal stromal tumors in the imatinib era: 15 years' experience of a tertiary center
    Peixoto, Armando
    Costa-Moreira, Pedro
    Silva, Marco
    Santos, Ana Luisa
    Lopes, Susana
    Vilas-Boas, Filipe
    Moutinho-Ribeiro, Pedro
    Macedo, Guilherme
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (02) : 358 - 362